Showing 1 - 20 results of 173,573 for search '(( 25 c decrease ) OR ((( 5 ht decrease ) OR ( 10 ((we decrease) OR (_ decrease)) ))))', query time: 1.04s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7

    Changes in neural activity were decreased in animals pre-exposed to 5-HT and <i>mod-1</i> mutants when the worms switched their locomotive direction. by Haruka Mori (8082215)

    Published 2019
    “…(F) Decreasing levels of RID neural activity during the transition periods from forward to backward locomotion in mock, 5-HT pre-exposed (p = 1.3 × 10<sup>−3</sup>), and <i>mod-1</i> mutant (p = 5.4 × 10<sup>−4</sup>) animals. …”
  8. 8
  9. 9
  10. 10

    Dose and time dependent decrease in the viability of cancer cells upon treatment with vitamin D3. by Vidya G. Bettada (22208808)

    Published 2025
    “…Vitamin D3 inhibited the viability of SiHa cell line beginning from 62.5µM. The percentage reduction in the viability has reduced with increasing concentration of vitamin D (from 250µM). …”
  11. 11
  12. 12

    Pharmacological Mechanism of the Non-hallucinogenic 5‑HT<sub>2A</sub> Agonist Ariadne and Analogs by Michael J. Cunningham (14267038)

    Published 2022
    “…Compared to DOM, Ariadne shows lower signaling potency and efficacy in multiple signaling pathways examined (G<sub>q</sub>, G<sub>11</sub>, and β-arrestin2) coupled to 5-HT<sub>2A</sub> receptors. We confirmed the shift in signaling for an α-propyl analog and provide a molecular docking rationale for the progressive decrease in signaling potency with the growing length of the α-substituent. …”
  13. 13

    Pharmacological Mechanism of the Non-hallucinogenic 5‑HT<sub>2A</sub> Agonist Ariadne and Analogs by Michael J. Cunningham (14267038)

    Published 2022
    “…Compared to DOM, Ariadne shows lower signaling potency and efficacy in multiple signaling pathways examined (G<sub>q</sub>, G<sub>11</sub>, and β-arrestin2) coupled to 5-HT<sub>2A</sub> receptors. We confirmed the shift in signaling for an α-propyl analog and provide a molecular docking rationale for the progressive decrease in signaling potency with the growing length of the α-substituent. …”
  14. 14

    Supplementary Material for: Decreasing Attacks and Improving Quality of Life through a Systematic Management Program for Patients with Hereditary Angioedema by Nunes F.L. (10223465)

    Published 2021
    “…<b><i>Results:</i></b> Mean number of attacks/month significantly decreased (95% credible interval [CrI] excluding 0) from 1.15 preintervention to 0.25 and 0.23, 8 and 14 months within intervention, with mean decreases of −0.89 (95% CrI: −1.21 to −0.58) and −0.92 (95% CrI: −1.22 to −0.60), respectively. …”
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20